Silencing GPT2 could partly reverse the malignant proliferation and the activation of glycolysis pathway caused by SPTBN1 deletion, further supporting the role of SPTBN1-GPT2-mediated glycolysis in promoting ccRCC oncogenesis. The gene discussed is GPT2; the disease is nonpapillary renal cell carcinoma.